Healio3d
Vanzacaftor, tezacaftor, deutivacaftor similar to current cystic fibrosis standard of care
Please provide your email address to receive an email when new articles are posted on . Percent-predicted FEV 1, sweat chloride and safety were analyzed in two phase 3 trials of vanzacaftor ...
Monthly Prescribing Reference23d
FDA Approval Increases Eligibility for Cystic Fibrosis Medication Trikafta
Participants were randomly assigned to receive Trikafta or placebo based on age and weight: Aged 6 to <12 years and less than 30kg: morning dose of elexacaftor 100mg/tezacaftor 50mg/ivacaftor 75mg ...
The Business Journals26d
Vertex wins approval for new once-daily CF drug
It will be marketed as Alyftrek. Vertex also won expanded approval for Trikafta, which was first approved in 2019. Trikafta has become Vertex’s (Nasdaq: VRTX) blockbuster CF drug, helping drive ...
Benzinga.com4d
Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
FDA approval of ALYFTREK and TRIKAFTA expands CF treatment options to over 300 mutations, benefiting 300 newly eligible U.S. patients. Suzetrigine for acute pain aligns with NOPAIN Act ...
Nasdaq29d
Vertex announces FDA exands approval for Trikafta
Vertex Pharmaceuticals (VRTX) announced the U.S. Food and Drug Administration has approved the expanded use of Trikafta for the treatment of people with cystic fibrosis ages 2 and older who have ...
Reuters1mon
US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment
The approval also helps shield from erosion of sales when Trikafta loses its patent, said William Blair analyst Myles Minter ahead of the decision. Cystic fibrosis is an inherited disease in which ...